All In Biotech

NDA 215239 · Catalyst Pharms

Agamree

Vamorolone · Oral

NovelOrphan

CDER novel approval, Oct 26, 2023: To treat Duchenne muscular dystrophy

Last checked: Nov 19, 2026Latest source record: Jun 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Oct 26, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

10

0 Phase 3, 1 recruiting

FAERS reports

1,745

453 serious, 32 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 22, 2026.

AGAMREE is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. AGAMREE is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. ( 1 )

Mechanism: Vamorolone is a corticosteroid that acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The precise mechanism by which vamorolone exerts its effect in patients with DMD is unknown.

Therapeutic areas: Neurology · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 26, 2023 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
  • AGAMREE · VAMOROLONE 40MG/ML · SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vamorolone" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • weight increased283
  • product dose omission issue120
  • vomiting110
  • asthenia84
  • pyrexia74
  • influenza72
  • fatigue71
  • duchenne muscular dystrophy67
  • abdominal pain upper66
  • increased appetite65
  • diarrhoea63
  • headache62

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20222
20233
2024377
2025849
2026514

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Agamree (Vamorolone)

2024 spending

$699K

Beneficiaries

n/a

41 claims

Per beneficiary

n/a

$97.07 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$698,932

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 21 on PubMed

Sponsor: Catalyst Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.